Phosphodiesterase 4 in osteoblastic osteosarcoma cells as a potential target for growth inhibition

Reverse transcription-polymerase chain reaction (RT-PCR) analysis revealed that HOSM-1 cells, an osteosarcoma cell line established from human mandible, expressed mRNA for osteoblastic markers, such as alkaline phosphatase, osteonectin, osteocalcin and parathyroid hormone receptor, thus exhibiting an osteoblastic phenotype. We have investigated a possible role of cyclic nucleotide phosphodiesterases (PDEs) in osteosarcoma cells. RT-PCR analysis revealed that HOSM-1 cells expressed mRNA for PDE4A, 4B and 4C. In addition, rolipram, a specific inhibitor of PDE4, inhibited HOSM-1 cell proliferation. The finding that PDE4 is involved in proliferation of osteosarcoma cells suggests the possibility that PDE4 may be a new target for antitumor therapy.

[1]  V. Manganiello,et al.  Characterization of phosphodiesterase 3 in human malignant melanoma cell line. , 2002, Anticancer research.

[2]  K. Takaoka,et al.  Involvement of Phosphodiesterase Isozymes in Osteoblastic Differentiation , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  K. Takaoka,et al.  Phosphodiesterase inhibitors, pentoxifylline and rolipram, increase bone mass mainly by promoting bone formation in normal mice. , 2000, Bone.

[4]  P. Speight,et al.  Osteosarcoma of the jaws: a 30-year retrospective review. , 2000, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[5]  C. Lamberg-Allardt,et al.  Regulation of adenosine 3',5'-cyclic monophosphate (cAMP) accumulation in UMR-106 osteoblast-like cells: role of cAMP-phosphodiesterase and cAMP efflux. , 1999, Biochemical pharmacology.

[6]  E. Degerman,et al.  Cyclic nucleotide phosphodiesterases (PDE) 3 and 4 in normal, malignant, and HTLV-I transformed human lymphocytes. , 1999, Biochemical pharmacology.

[7]  E. Degerman,et al.  Cyclic Nucleotide Phosphodiesterases (PDEs): Diverse Regulators of Cyclic Nucleotide Signals and Inviting Molecular Targets for Novel Therapeutic Agents , 1999, Thrombosis and Haemostasis.

[8]  Ken Takeda,et al.  The effect of papaverine on morphologic differentiation, proliferation and invasive potential of human prostatic cancer LNCaP cells , 1999, International journal of urology : official journal of the Japanese Urological Association.

[9]  M. McKee,et al.  Mice Lacking Osteopontin Show Normal Development and Bone Structure but Display Altered Osteoclast Formation In Vitro , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  K. Ohya,et al.  Reduction of bone loss by denbufylline, an inhibitor of phosphodiesterase 4. , 1997, Biochemical pharmacology.

[11]  M. Billah,et al.  Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D. , 1997, Biochemical and biophysical research communications.

[12]  M. Ohishi,et al.  Establishment and characterisation of an osteoblastic clonal cell line from human mandibular osteosarcoma (HMOS-1). , 1997, Oral oncology.

[13]  P. Bonnet,et al.  Dissociation between phosphodiesterase inhibition and antiproliferative effects of phosphodiesterase inhibitors on the Dami cell line. , 1997, Biochemical pharmacology.

[14]  C. Lamberg-Allardt,et al.  Rapid Protein Kinase A—Mediated Activation of Cyclic AMP‐Phosphodiesterase by Parathyroid Hormone in UMR‐106 Osteoblast‐like Cells , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  D. B. Evans,et al.  PCR phenotyping of cytokines, growth factors and their receptors and bone matrix proteins in human osteoblast-like cell lines. , 1996, Bone.

[16]  B. Riggs,et al.  Isolation and characterization of osteoblast precursor cells from human bone marrow , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  J. Polson,et al.  Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. , 1994, Biochemical pharmacology.

[18]  L. Quarles,et al.  Molecular to pharmacologic control of osteoblast proliferation and differentiation , 1994, Journal of cellular biochemistry.

[19]  E. Degerman,et al.  Single-step affinity purification, partial structure and properties of human platelet cGMP inhibited cAMP phosphodiesterase. , 1994, Biochimica et biophysica acta.

[20]  G S Stein,et al.  Molecular mechanisms mediating proliferation/differentiation interrelationships during progressive development of the osteoblast phenotype. , 1993, Endocrine reviews.

[21]  G. Eisenbrand,et al.  3',5'-Cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition. , 1993, Cancer research.

[22]  K. D. Devine,et al.  Osteosarcoma of the jaw , 1983, Cancer.

[23]  M. Giorgi,et al.  Phosphodiesterase specific inhibitors control cell growth of a human neuroepithelioma cell line , 2004, Journal of Neuro-Oncology.

[24]  B. Czerniak,et al.  Bone cancers , 1995, Cancer.

[25]  Toshio Tagawa,et al.  Primary malignant melanoma of the oral cavity. Case report and establishment of melanoma cell line. , 1981, International journal of oral surgery.